I haven't ever been invested in a PH play and it's likely I never will. It's not my job to deride him for the egregious treatment of retail holders.
Since listing, PH has paid himself $1,039,299.
During that time, CHM has spent $35,474,712 on R&D. I'm not sure what the guy's tax liabilities have been, but assume the entire $1.03m was taxed at the highest marginal tax rate of 45% ($570k in hand) and he's effectively just acquired himself an additional >$5m of that CHM R&D spend for $430k out of pocket - and this was after positive trial results were announced. It doesn't matter how great the opportunity is if you never get to see any of the upside.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $10.07M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.08K | 2.623M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4706271 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14960701 | 24 |
View Market Depth
| Last trade - 11.14am 23/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |